DIRS.INFO The most relevant business & tech news

☆ Jefferies says buy this pharmaceutical play, sees more than 100% upside from here
▼ + stars: | 2024-11-19 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Aclaris Therapeutics' recent drug developments could spell more gains ahead, according to Jefferies. Analyst Roger Song upgraded the stock to buy from hold and hiked his price target by $5 to $7, implying about 123% upside from Monday's close. ACRS YTD mountain ACRS, year-to-date Song specifically pointed to the strength of its BSI-045B treatment, which is an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody for atopic dermatitis (AD). If success, BSI-045B could be the 1st anti-TSLP in the crowded AD space providing differentiated [mechanism of action] [with] improved efficacy [and] safety." This comes as the company announced on Monday that it entered into an exclusive license agreement with Biosion for worldwide rights, excluding greater China, to both that drug and its other anti-TSLP drug known as BSI-502.

Persons: Roger Song, Biosion, Jefferies, Piper Sandler, Christopher Raymond, derm Organizations: Therapeutics, Jefferies, BSI Locations: China, Aclaris

☆ Aclaris shares plummet on terminating development of rheumatoid arthritis drug
▼ + stars: | 2023-11-13 | by ( ) www.reuters.com time to read: +1 min

Companies Aclaris Therapeutics Inc FollowNov 13 (Reuters) - Aclaris Therapeutics (ACRS.O) on Monday said it would stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial, sending its shares plunging 84% before the bell. The trial tested two doses of the drug, zunsemetinib, along with anti-rheumatic drug methotrexate compared to placebo and methotrexate in patients with moderate to severe rheumatoid arthritis who have inadequate response to methotrexate alone. There was no notable differentiation between zunsemetinib and placebo across any measures of efficacy at 12 weeks, the company said. The company will also be halting enrollment in an ongoing mid-stage trial studying the drug in psoriatic arthritis. The drug developer said it is also studying its drug ATI-1777 in patients with moderate to severe atopic dermatitis which is currently in mid-stage trial.

Persons: Sriparna Roy, Maju Samuel Organizations: Aclaris Therapeutics, ATI, Thomson Locations: Bengaluru

☆ Evercore ISI says this biotech stock is a high risk, high reward play, with more than 200% upside
▼ + stars: | 2023-10-03 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +2 min

Evercore ISI initiated coverage of Aclaris Therapeutics , a clinical stage biotech working on immunology and inflammation drugs, at an outperform, saying the market is underpricing its odds for success heading into the release of clinical trial data. Admittedly, the upcoming trial results may not be successful, which makes the bet a risky one, he said. If Aclaris is successful with zunsemetinib, it will be the only MK2 inhibitor on the market for rheumatoid arthritis, which Evercore ISI sees as an advantage. A similar drug from Bristol Myers Squibb wasn't successful in a different form of arthritis. Evercore ISI expects investors are only pricing in a 20% chance of positive data from the clinical trial, whereas the firm expects the odds are closer to 50%.

Persons: Gavin Clark, Clark, Gartner, zunsemetinib, Aclaris, Bristol Myers Squibb wasn't, — CNBC's Michael Bloom Organizations: Evercore ISI, Aclaris Therapeutics, Gartner, Clark, Bristol Myers Squibb

☆ Here are Tuesday's biggest analyst calls: Nvidia, Rivian, Amazon, Airbnb, Warby Parker, HP, FedEx and more
▼ + stars: | 2023-10-03 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Here are Tuesday's biggest calls on Wall Street: KeyBanc reiterates Nvidia as overweight KeyBanc raised its price target on Nvidia to $750 per share from $670 and said it sees "outsized growth." Bank of America adds FedEx to the US1 list Bank of America added the stock to its top picks list. "Upgrading Clean Energy Fuels (CLNE) from Outperform to Strong Buy, with the company on the cusp of ramping up in-house RNG production." JPMorgan reiterates Amazon as a top pick JPMorgan said ignore the noise and buy the dip in shares of Amazon. Bank of America initiates Dycom as buy Bank of America said in its initiation of the telecommunications infrastructure company that it's uniquely positioned.

Persons: KeyBanc, Ally, Evercore, bode, Stifel, Churchill, CHDN, Raymond James, Baird, Vestis, Piper Sandler, Tesla, IBKR, Morgan Stanley, Rivian, it's, Warby Parker, Booz Allen Hamilton, Goldman Sachs, Wedbush Organizations: Nvidia, Aclaris Therapeutics, ISI, Citi, Arista Networks, Arista, " Bank of America, FedEx, Bank of America, FedEx Corp, Owl Capital, Swift Transportation, Evercore ISI, TAM, Energy Fuels, JPMorgan, FTC, DOJ, HP Inc, underperform Bank of America, HPQ, UBS, Booz, of America, Emerson Electric, Warner Music Group, Apple, Constellation Brands Locations: China, CY23

☆ Aclaris shares tank as skin disorder drug fails mid-stage study
▼ + stars: | 2023-03-06 | by ( ) www.reuters.com time to read: +1 min

Companies Aclaris Therapeutics Inc FollowMarch 6 (Reuters) - Aclaris Therapeutics Inc (ACRS.O) said on Monday its experimental drug failed to meet the main goal of a mid-stage study to treat a painful skin disorder, sending its shares tumbling more than 36% in premarket trading. The drug, zunsemetinib, did not meet the main goal of reducing abscesses in patients with moderate to severe hidradenitis suppurativa (HS) at week 12, compared with a placebo. HS is a chronic inflammatory skin condition that causes abscesses and scarring on the skin. The study also failed to meet its secondary goals, which included percentage of patients who achieved at least a 50% reduction in number of inflammatory lesions, Aclaris said. The drug is being tested to treat other inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis, far bigger markets than HS.

☆ This under-the-radar stock can surge more than 60% on a possible treatment for immuno-inflammatory diseases, Goldman Sachs says
▼ + stars: | 2022-12-01 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Shares of Aclaris Therapeutics can surge more than 60% on the back of a possible new treatment for immuno-inflammatory diseases, including rheumatoid arthritis, according to Goldman Sachs. Analyst Corinne Jenkins initiated coverage of Aclaris Therapeutics with a buy rating, saying she expects promising results out of clinical trials for the company's drug called zunsemetinib . The biopharma stock has already outperformed this year, up nearly 5% in 2022, while the S & P 500 declined roughly 14%. The analyst expects that there will be further catalysts for positive upside as the Aclaris unveils further data for zunsemetinib in 2023. "We see this profile as sufficient to garner modest share in these large indications, fostering a sizable peak sales opportunity which we estimate at > $5B across indications," Jenkins wrote.

☆ Stocks making the biggest moves midday: Salesforce, Five Below, Okta, Costco and more
▼ + stars: | 2022-12-01 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Salesforce did report earnings and revenue that beat analyst expectations for the most recent quarter, however. Costco – Shares of retailer Costco shed nearly 6% after the company reported softer-than-expected sales figures for November that could signal a weak consumer heading into the holiday shopping season. The cloud data platform provider reported earnings that beat expectations but provided light revenue guidance, which sent the stock lower after-hours Wednesday. The company reported 29 cents of earnings per share on $645 million of revenue. The lingerie company reported earnings of 29 cents per share on revenue of $1.32 billion.

Search resuls for: "Aclaris"

7 mentions found